Hycamtin - Big Patent Expirations of 2010

Drug: Hycamtin
Company: GlaxoSmithKline
Indication: Ovarian and small-cell lung cancer
Expiration Date: May 28/Pediatric Exclusivity through Nov. 28

Summary: The '758 patent covering Hycamtin enjoys pediatric exclusivity until November. However, according to the [email protected] website, no generic company has tentative approval for Hycamtin, which is used to treat ovarian and small-cell lung cancer. The product had sales of $72 million in 2009, according to a GSK earnings statement. Teva has tried to get samples of the drug to see if it can make a copy, but GSK has refused. The FTC said last fall it would look into to see whether GSK's actions unfairly thwart competition.

Hycamtin - Big Patent Expirations of 2010
Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.